NO892303L - Stabilisert fgf-sammensetning og fremstilling derav. - Google Patents

Stabilisert fgf-sammensetning og fremstilling derav.

Info

Publication number
NO892303L
NO892303L NO89892303A NO892303A NO892303L NO 892303 L NO892303 L NO 892303L NO 89892303 A NO89892303 A NO 89892303A NO 892303 A NO892303 A NO 892303A NO 892303 L NO892303 L NO 892303L
Authority
NO
Norway
Prior art keywords
mutein
fgf
sulfate
glucan
amino acid
Prior art date
Application number
NO89892303A
Other languages
English (en)
Norwegian (no)
Other versions
NO892303D0 (no
Inventor
Koichi Kato
Kenji Kawahara
Tomoko Kajio
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO892303D0 publication Critical patent/NO892303D0/no
Publication of NO892303L publication Critical patent/NO892303L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Fodder In General (AREA)
NO89892303A 1988-06-06 1989-06-05 Stabilisert fgf-sammensetning og fremstilling derav. NO892303L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13890788 1988-06-06
JP18577288 1988-07-25

Publications (2)

Publication Number Publication Date
NO892303D0 NO892303D0 (no) 1989-06-05
NO892303L true NO892303L (no) 1989-12-07

Family

ID=26471846

Family Applications (1)

Application Number Title Priority Date Filing Date
NO89892303A NO892303L (no) 1988-06-06 1989-06-05 Stabilisert fgf-sammensetning og fremstilling derav.

Country Status (14)

Country Link
US (1) US5314872A (de)
EP (1) EP0345660B1 (de)
JP (1) JP2929200B2 (de)
KR (1) KR910001044A (de)
CN (1) CN1038765A (de)
AT (1) ATE79762T1 (de)
AU (1) AU614137B2 (de)
CA (1) CA1329763C (de)
DE (1) DE68902583T2 (de)
DK (1) DK246589A (de)
FI (1) FI892727A7 (de)
HU (1) HU205144B (de)
IL (1) IL90348A0 (de)
NO (1) NO892303L (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
US5175147A (en) * 1988-08-19 1992-12-29 Takeda Chemical Industries, Ltd Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract
US5217954A (en) * 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
US5714458A (en) * 1990-07-18 1998-02-03 Farmitalia Carlo Erba S.R.L. Stable pharmaceutical compositions containing a fibroblast growth factor
GB9015824D0 (en) * 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
GB9102107D0 (en) * 1991-01-31 1991-03-13 Erba Carlo Spa Stabilisation of fibroblast growth factor using a polysaccharide
AU1052492A (en) * 1991-01-31 1992-08-06 Farmitalia Carlo Erba S.R.L. Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent
JPH0771459B2 (ja) * 1991-05-15 1995-08-02 三協食品工業株式会社 機能性食品素材とその製造方法
US5705178A (en) * 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
DE4121043A1 (de) * 1991-06-26 1993-01-07 Merck Patent Gmbh Knochenersatzmaterial mit fgf
CA2080538A1 (en) * 1991-10-21 1993-04-22 Joseph V. Bondi Lyophilized acidic fibroblast growth factor
CA2080537A1 (en) * 1991-10-21 1993-04-22 David B. Volkin Stabilized topical acidic fibroblast growth factor formulation
EP0612249A4 (en) * 1991-11-11 1995-11-08 Univ Pennsylvania Methods of inhibiting restenosis.
US5482929A (en) * 1991-12-26 1996-01-09 Kaken Pharmaceutical Co., Ltd. Composition of stabilized fibroblast growth factor
HUT67217A (en) * 1992-02-14 1995-03-28 Kaken Pharma Co Ltd Remedy for airway diseases
DE4242889A1 (de) * 1992-12-18 1994-06-23 Merck Patent Gmbh Hohlendoprothesen mit Knochenwachstumsfördernder Füllung
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
JPH11130636A (ja) * 1997-10-28 1999-05-18 Noevir Co Ltd 毛髪用化粧料
JP2002512200A (ja) * 1998-04-17 2002-04-23 アンジオジェニックス, インコーポレイテッド 治療的な脈管形成因子およびその使用方法
US6440934B1 (en) * 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US8618052B2 (en) 1998-10-13 2013-12-31 Novartis Vaccines And Diagnostics, Inc. Method of treating coronary artery disease by administering FGF-5
AU6411199A (en) * 1998-10-13 2000-05-01 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
US20030166550A1 (en) * 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
AU6634400A (en) * 1999-08-13 2001-03-13 Chiron Corporation Dose of an angiogenic factor and method of administering to improve myocardial blood flow
WO2002017956A2 (en) * 2000-08-31 2002-03-07 Chiron Corporation Stabilized fgf formulations containing reducing agents
MX2007013725A (es) 2005-05-05 2008-04-09 Sensient Flavors Inc Produccion de beta-glucanos y mananos.
MY143274A (en) 2005-12-22 2011-04-15 Genentech Inc Recombinant production of heparin binding proteins
CN102076352B (zh) * 2008-05-02 2016-06-15 西安大略大学 与血管有关的fgf-9和它的用途
FR2948286B1 (fr) 2009-07-27 2011-08-26 Jean-Noel Thorel Composition injectable associant un agent de comblement et un milieu de croissance des fibroblastes
FR2954165B1 (fr) * 2009-12-18 2012-01-13 Jean-Noel Thorel Compositions injectables a usage intra-articulaire associant un agent de viscosupplementation et un milieu de croissance des fibroblastes
SG10201706813WA (en) 2012-03-30 2017-10-30 Ajinomoto Kk Culture medium for proliferating stem cell, which contains sulfated compound
CN105288591A (zh) * 2015-10-29 2016-02-03 段懿玲 碱性成纤维细胞生长因子组合物及其在制备治疗脊髓损伤的药物中的应用
US11746135B2 (en) 2015-11-27 2023-09-05 Masarykova Univerzita Thermostable FGF2 polypeptide, use thereof
WO2017104567A1 (ja) * 2015-12-15 2017-06-22 協和メデックス株式会社 線維芽細胞増殖因子-23の安定化剤
CN110709520B (zh) 2017-04-21 2024-04-05 株式会社柳韩洋行 用于产生双功能蛋白质及其衍生物的方法
US12498366B2 (en) 2017-05-31 2025-12-16 Canon Medical Diagnostics Corporation Measurement method for fibroblast growth factor-23 by forming immunocomplexes
JP7177696B2 (ja) * 2018-12-28 2022-11-24 日清ファルマ株式会社 生理活性ペプチド又は生理活性タンパク質の活性低下抑制剤
CN110151977B (zh) * 2019-05-29 2022-11-29 新乡医学院 一种保护aFGF蛋白药物稳定性和活性的方法
TWI865835B (zh) * 2020-11-16 2024-12-11 雅祥生技醫藥股份有限公司 穩定的酸性纖維母細胞生長因子組合物
EP4183796A1 (de) 2021-11-19 2023-05-24 Enantis s.r.o. Thermostabiles fgf10-polypeptid oder fragment davon, verwendung davon

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296100A (en) * 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
US4717717A (en) * 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
NZ222413A (en) * 1986-11-05 1991-06-25 Ethicon Inc Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser
US5013714A (en) * 1988-12-15 1991-05-07 Lindstrom Richard L Viscoelastic solution

Also Published As

Publication number Publication date
FI892727A0 (fi) 1989-06-02
FI892727L (fi) 1989-12-07
JPH02138223A (ja) 1990-05-28
KR910001044A (ko) 1991-01-30
AU614137B2 (en) 1991-08-22
HU205144B (en) 1992-03-30
ATE79762T1 (de) 1992-09-15
HUT52393A (en) 1990-07-28
EP0345660A1 (de) 1989-12-13
CA1329763C (en) 1994-05-24
IL90348A0 (en) 1989-12-15
DE68902583T2 (de) 1993-01-21
NO892303D0 (no) 1989-06-05
EP0345660B1 (de) 1992-08-26
FI892727A7 (fi) 1989-12-07
US5314872A (en) 1994-05-24
DE68902583D1 (de) 1992-10-01
AU3496989A (en) 1989-12-07
CN1038765A (zh) 1990-01-17
JP2929200B2 (ja) 1999-08-03
DK246589D0 (da) 1989-05-22
DK246589A (da) 1989-12-07

Similar Documents

Publication Publication Date Title
EP0345660B1 (de) Stabilisierte FGF-Zusammensetzung und deren Herstellung
US5951972A (en) Stabilization of somatotropins and other proteins by modification of cysteine residues
EP0281822B1 (de) Basic fibroblast growth factor mutein, DNS und deren Verwendung
EP0486862B1 (de) Chimeres Fibroblasten-Wachstumsfaktor
JPH08506095A (ja) 改変インシュリン様成長因子
JPH0240399A (ja) 線維芽細胞増殖因子ムテインの複合体あるいは組成物
US5223483A (en) Cysteine-modified acidic fibroblast growth factor
JPH08301899A (ja) Igf−1スーパーアゴニスト
KR20190036956A (ko) 지속형 단쇄 인슐린 아날로그 및 이의 결합체
US5120715A (en) Method for purifying fibroblast growth factor protein
DK174961B1 (da) Fibroblast-vækstfaktor, nucleotidsekvens kodende derfor, præparat indeholdende faktoren og fremgangsmåde til fremstilling deraf
EP0326907A1 (de) Polypeptide, DNA und ihre Verwendung
US5409897A (en) Cysteine-modified acidic fibroblast growth factor and methods of use
KR20200078414A (ko) 인슐린 및 글루카곤을 포함하는 약학 조성물
US6531134B1 (en) Mammalian milk growth factor
EP0421455A1 (de) Mutein von HST-1 und seine Herstellung
WO2022250556A4 (en) Human fibroblast growth factor 1 (fgf-1) muteins, their dimers and uses
US5852177A (en) Basic fibroblast growth factor (bFGF) muteins
CA2115522A1 (en) Hst-2 mutein, dna coding for the same and preparation thereof
JP2832354B2 (ja) ムテイン,dnaおよびその用途
JPH02276588A (ja) 線維芽細胞成長因子蛋白質の精製法
JPH07126293A (ja) hst−2ムテイン、その製造法および用途
DK166730B (da) Humaninsulinanaloger og deres farmaceutisk tolerable salte samt farmaceutiske praeparater indeholdende disse
JPH03184998A (ja) ハイブリッド蛋白質,dnaおよびその用途